"The rising cost of new drug development -- about $2.6 billion per drug -- is making drug companies make a rational decision to emphasize products where they are likely to make their money back, and that's not going to be in antibiotics," Kinch said. "Drug companies may also be saying, 'We are not making much money on antibiotics, so why bother to stock that product.'" Read more at http://www.philly.com/philly/health/HealthDay698691_20150423_Antibiotic_Shortages_On_the_Rise_in_U_S_.html#DyD46CMjUVi4CLxP.99